Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?

Introduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-niv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ucar, Gokhan, Acikgoz, Yusuf, Ergun, Yakup, Bal, Oznur, Yilmaz, Mesut, Karakaya, Serdar, Akdeniz, Nadiye, Kostek, Osman, Aydin Isak, Ozlem, Yazici Sener, Gorkem, Dirikoc, Merve, Aktürk Esen, Selin, Dogan, Mutlu, Uncu, Dogan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Radiation Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574822/
https://www.ncbi.nlm.nih.gov/pubmed/33094066
http://dx.doi.org/10.7759/cureus.10525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574822/
https://www.ncbi.nlm.nih.gov/pubmed/33094066
http://dx.doi.org/10.7759/cureus.10525

Ejemplares similares